Is hyaluronic acid the perfect excipient for the pharmaceutical need?

被引:25
|
作者
Harrer, Daniela [1 ]
Armengol, Eva Sanchez [1 ]
Friedl, Julian D. [1 ]
Jalil, Aamir [1 ]
Jelkmann, Max [1 ]
Leichner, Christina [1 ]
Laffleur, Flavia [1 ]
机构
[1] Univ Innsbruck, Inst Pharm, Dept Pharmaceut Technol, Innrain 80-82, A-6020 Innsbruck, Austria
关键词
Hyaluronic acid; Modification; Mucoadhesion; Polymer; Structure; Thiomers; Tissue; TARGETED DRUG-DELIVERY; ANTICANCER DRUG; HYBRID HYDROGEL; OVARIAN-CANCER; IN-VITRO; NANOPARTICLES; TUMOR; PACLITAXEL; CONJUGATE; MUCOADHESIVE;
D O I
10.1016/j.ijpharm.2021.120589
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Hyaluronic acid has become an interesting and important polymer as an excipient for pharmaceutical products due to its beneficial properties, like solubility, biocompatibility and biodegradation. To improve the properties of hyaluronic acid, different possibilities for chemical modifications are presented, and the opportunities as novel systems for drug delivery are discussed. This review gives an overview over the production of hyaluronic acid, the possibilities of its chemical modification and the current state of in vitro and in vivo research. Furthermore, market approved and commercially available products are reviewed and derivatives undergoing clinical trials and applying for market approval are shown. In particular, hyaluronic acid has been studied for different administrations in rheumatology, ophthalmology, local anesthetics, cancer treatment and bioengineering of tissues. The present work concludes with perspectives for future administration of pharmaceuticals based on hyaluronic acid.
引用
下载
收藏
页数:13
相关论文
共 50 条
  • [41] Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing
    Andres Bejarano
    Chandima Hewa Nadungodage
    Fang Wang
    Ann Christine Catlin
    Stephen W. Hoag
    AAPS PharmSciTech, 20
  • [42] Phosphoric acid mediated depolymerization and decrystallization of cellulose: Preparation of low crystallinity cellulose - A new pharmaceutical excipient
    Wei, S
    Kumar, V
    Banker, GS
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 142 (02) : 175 - 181
  • [43] Bridging the Gap: A Comparative Investigation of Pharmaceutical Excipient Regulations
    Mali, Ashwin
    Kuvar, Vijaykumar
    Bharadwaj, Saily
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2024, 58 (02) : 258 - 272
  • [44] Decision Support for Excipient Risk Assessment in Pharmaceutical Manufacturing
    Bejarano, Andres
    Nadungodage, Chandima Hewa
    Wang, Fang
    Catlin, Ann Christine
    Hoag, Stephen W.
    AAPS PHARMSCITECH, 2019, 20 (06)
  • [45] Bridging the Gap: A Comparative Investigation of Pharmaceutical Excipient Regulations
    Ashwin Mali
    Vijaykumar Kuvar
    Saily Bharadwaj
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 258 - 272
  • [46] Quantification of hyaluronic acid fragments in pharmaceutical formulations using LC-ESI-MS
    Kühn, AV
    Raith, K
    Sauerland, V
    Neubert, RHH
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 30 (05) : 1531 - 1537
  • [47] Development and validation of an HPLC method for the determination of hyaluronic acid active substance in pharmaceutical formulations
    Caglar, Emre Sefik
    Okur, Neslihan Ustundag
    Karasulu, Hatice Yesim
    JOURNAL OF RESEARCH IN PHARMACY, 2022, 26 (01): : 112 - 122
  • [48] Hyaluronic acid in the treatment and prevention of skin diseases:: Molecular biological, pharmaceutical and clinical aspects
    Weindl, G
    Schaller, M
    Schäfer-Korting, M
    Korting, C
    SKIN PHARMACOLOGY AND PHYSIOLOGY, 2004, 17 (05) : 207 - 213
  • [49] New approaches for quantifying hyaluronic acid in pharmaceutical semisolid formulations using HPLC and CZE
    Alkrad, JA
    Merstani, Y
    Neubert, RHH
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 30 (04) : 913 - 919